Thousand Oaks, CA, United States of America

Shanaka Stanislaus

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Innovations of Shanaka Stanislaus in Metabolic Disorder Treatments

Introduction

Shanaka Stanislaus is an accomplished inventor based in Thousand Oaks, CA. He has made significant contributions to the field of metabolic disorder treatments, holding two patents that focus on innovative methods for addressing various metabolic diseases.

Latest Patents

His latest patents include a method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR). This method provides a composition that comprises an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist. The metabolic diseases targeted by this invention include type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, and diabetic nephropathy. The composition may also include an antibody or functional fragment that contains a cysteine at one or more conjugation sites, allowing for effective conjugation of the GLP-1 receptor agonist.

Career Highlights

Shanaka Stanislaus is currently employed at Amgen Inc., where he continues to develop innovative solutions for metabolic disorders. His work is characterized by a strong focus on scientific research and practical applications that can significantly improve patient outcomes.

Collaborations

He collaborates with talented coworkers, including Yuan Cheng and Chawita Netirojjanakul, who contribute to the advancement of research in this vital area of healthcare.

Conclusion

Shanaka Stanislaus is a notable inventor whose work in metabolic disorder treatments showcases the potential of innovative approaches in medicine. His patents reflect a commitment to improving health outcomes for individuals affected by metabolic diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…